Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,132Revenue $M619Net Margin (%)-4.9Z-Score11.1
Enterprise Value $M8,858EPS $-0.2Operating Margin %-14.1F-Score2
P/E(ttm))0Cash Flow Per Share $0.0Pre-tax Margin (%)-2.3Higher ROA y-yN
Price/Book6.510-y EBITDA Growth Rate %0Quick Ratio6.3Cash flow > EarningsY
Price/Sales14.55-y EBITDA Growth Rate %0Current Ratio6.7Lower Leverage y-yN
Price/Cash Flow725y-y EBITDA Growth Rate %-1.5ROA % (ttm)-2.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-2.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M148ROI % (ttm)-2.4Gross Margin Increase y-yN

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALKSKen Fisher 2014-09-30 Add$41.54 - $51.52
($44.73)
$ 61.6727%Add 75.86%97,264
ALKSVanguard Health Care Fund 2014-06-30 Add0.13%$41.1 - $50.94
($46.06)
$ 61.6725%Add 18.45%6,135,913
ALKSKen Fisher 2014-06-30 Buy 0.01%$41.1 - $50.94
($46.06)
$ 61.6725%New holding55,309
ALKSJohn Burbank 2014-06-30 Sold Out -0.01%$41.1 - $50.94
($46.06)
$ 61.6725%Sold Out0
ALKSVanguard Health Care Fund 2014-03-31 Add0.19%$40.07 - $53.82
($47.32)
$ 61.6723%Add 41.07%5,180,238
ALKSJohn Burbank 2014-03-31 Buy 0.01%$40.07 - $53.82
($47.41)
$ 61.6723%New holding4,651
ALKSVanguard Health Care Fund 2013-12-31 Add0.1%$30.17 - $41.12
($36.93)
$ 61.6740%Add 28.18%3,672,087
ALKSVanguard Health Care Fund 2013-09-30 Add0.07%$28.66 - $35.35
($32.58)
$ 61.6747%Add 26.21%2,864,896
ALKSJoel Greenblatt 2013-09-30 Sold Out -0.03%$28.66 - $35.35
($32.58)
$ 61.6747%Sold Out0
ALKSVanguard Health Care Fund 2013-06-30 Add0.11%$22.35 - $33.72
($29.15)
$ 61.6753%Add 84.09%2,269,902
ALKSJoel Greenblatt 2013-06-30 Buy 0.03%$22.35 - $33.72
($29.15)
$ 61.6753%New holding26,624
ALKSVanguard Health Care Fund 2013-03-31 Add0.04%$18.52 - $23.81
($21.87)
$ 61.6765%Add 47.24%1,233,024
ALKSJohn Burbank 2012-03-31 Sold Out -0.23%$16.14 - $19.5
($16.48)
$ 61.6773%Sold Out0
ALKSVanguard Health Care Fund 2012-03-31 Buy 0.07%$16.14 - $19.5
($16.48)
$ 61.6773%New holding787,900
ALKSDaniel Loeb 2010-06-30 Sold Out -0.92%$10.7 - $13.75
($12.33)
$ 61.6780%Sold Out0
ALKSDaniel Loeb 2010-03-31 Buy 0.92%$9.41 - $14.01
($11.62)
$ 61.6781%New holding1,000,000
ALKSJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$9.41 - $14.01
($11.62)
$ 61.6781%Sold Out0
ALKSGeorge Soros 2010-03-31 Sold Out $9.41 - $14.01
($11.62)
$ 61.6781%Sold Out0
ALKSDaniel Loeb 2009-12-31 Sold Out -0.37%$7.58 - $9.88
($8.72)
$ 61.6786%Sold Out0
ALKSGeorge Soros 2009-12-31 Buy $7.58 - $9.88
($8.72)
$ 61.6786%New holding22,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALKS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cooke ShanePresident, Alkermes plc 2015-03-23Sell18,000$65.33-3.66view
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2015-03-16Sell18,000$66.81-5.79view
FRATES JAMES MSVP & CFO, Alkermes plc 2015-03-10Sell10,000$66.25-5view
Peterson RebeccaSVP, Corporate Communications 2015-03-05Sell17,737$71.37-11.81view
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. 2015-03-02Sell15,000$71.39-11.84view
BREYER ROBERT ADirector 2015-03-02Sell5,000$70.86-11.18view
Cooke ShanePresident, Alkermes plc 2015-02-23Sell18,000$74.29-15.28view
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc. 2015-02-17Sell18,000$70.87-11.19view
FRATES JAMES MSVP & CFO, Alkermes plc 2015-02-03Sell10,000$70.83-11.14view
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. 2015-02-02Sell15,000$72.01-12.6view

Press Releases about ALKS :

    Quarterly/Annual Reports about ALKS:

    News about ALKS:

    Articles On GuruFocus.com
    wait for positive ea Apr 06 2013 
    comment on ALKS Mar 09 2013 
    Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
    Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 09 2011 
    Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
    Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 06 2010 
    Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
    Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
    Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
    Opportunistic Coat-tailing Jan 05 2010 

    More From Other Websites
    Alkermes plc -- Moody's affirms Alkermes' Ba3 ratings; changes outlook to stable Mar 23 2015
    Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on... Mar 23 2015
    Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on... Mar 23 2015
    Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on... Mar 23 2015
    Alkermes Streamlines Operations, Revises 2015 Guidance - Analyst Blog Mar 10 2015
    Alkermes to Sell Plant to Recro Pharma Mar 09 2015
    Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. Mar 09 2015
    ALKERMES PLC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Mar 09 2015
    Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. Mar 09 2015
    Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. Mar 09 2015
    Cramer: Best of biotech Mar 04 2015
    Alkermes Intends to Add New Candidate to its Pipeline - Analyst Blog Mar 03 2015
    Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 03 2015
    Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 03 2015
    Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 03 2015
    ALKERMES PLC. Financials Mar 03 2015
    Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation,... Mar 02 2015
    Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation,... Mar 02 2015
    Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation,... Mar 02 2015
    Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Feb 26 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK